AXIN2 Antibody
| Code | Size | Price |
|---|
| PSI-6163-0.02mg | 0.02mg | £150.00 |
Quantity:
| PSI-6163-0.1mg | 0.1mg | £449.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Isotype: IgG
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunofluorescence (IF)
- Immunohistochemistry (IHC)
- Western Blot (WB)
Documents
Further Information
Additional Names:
AXIN2 Antibody: AXIL, ODCRCS, Axin-2, Axin-like protein, Axil
Application Note:
AXIN2 antibody can be used for detection of AXIN2 by Western blot at 1 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in mouse and rat samples and Immunofluorescence in mouse and rat samples. All other applications and species not yet tested.
Antibody validated: Western Blot in mouse samples; Immunohistochemistry in mouse and rat samples and Immunofluorescence in mouse and rat samples. All other applications and species not yet tested.
Background:
AXIN2 Antibody: Like the related protein AXIN1, AXIN2 is thought to play an important role in the regulation of the stability of beta-catenin in the Wnt signaling pathway. In mouse, AXIN2 organizes a multiprotein complex of APC (adenomatous polyposis of the colon), beta-catenin, glycogen synthase kinase 3-beta, and AXIN2, which leads to the degradation of beta-catenin, which is thought to be an important event in the genesis of a number of malignancies. The AXIN2 gene has been mapped to 17q23-q24, a region that shows frequent loss of heterozygosity in breast cancer, neuroblastoma, and other tumors. Mutations in this gene have been associated with colorectal cancer with defective mismatch repair.
Background References:
- Katoh M and Katoh M. WNT signaling pathway and stem cell signaling network. Clin. Cancer Res.2007; 13:4042-5.
- Behrens J, Jerchow BA, Wurtele M, et al. Functional interaction of an axin homolog, conductin, with beta-catenin, APC, and GSK3beta. Science1998; 280:596-9.
- Hadjihannas MV and Behrens J. CIN by WNT: growth pathways, mitotic control and chromosome instability in cancer. Cell Cycle2006; 5:2077-81.
- Mai M, Qian C, Yokomizo A, et al. Cloning of the human homolog of conductin (AXIN2), a gene mapping to chromosome 17q23-q24. Genomics1999; 55:341-4.
Buffer:
AXIN2 Antibody is supplied in PBS containing 0.02% sodium azide.
Concentration:
1 mg/mL
Conjugate:
Unconjugated
DISCLAIMER:
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
Homology:
Predicted species reactivity based on immunogen sequence: Chicken: (85%)
Immunogen:
AXIN2 antibody was raised against a 20 amino acid synthetic peptide near the carboxy terminus of human AXIN2.
The immunogen is located within amino acids 780 - 830 of AXIN2.
The immunogen is located within amino acids 780 - 830 of AXIN2.
NCBI Gene ID #:
8313
NCBI Official Name:
axin 2
NCBI Official Symbol:
AXIN2
NCBI Organism:
Homo sapiens
Physical State:
Liquid
PREDICTED MOLECULAR WEIGHT:
85, 93 kDa
Protein Accession #:
AAF22799
Protein GI Number:
195927059
Purification:
AXIN2 Antibody is affinity chromatography purified via peptide column.
Research Area:
Cancer,Cell Cycle
SPECIFICITY:
AXIN2 antibody is predicted to not cross-react with AXIN1. At least four isoforms of AXIN2 are known to exist; this antibody will recognize all four.
Swissprot #:
Q9Y2T1
User NOte:
Optimal dilutions for each application to be determined by the researcher.
Related Products
| Product Name | Product Code | Supplier | AXIN2 Peptide | PSI-6163P | ProSci | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|